Trials / Completed
CompletedNCT01749046
Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures
Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose of Remegal as Adjunctive Therapy in Patients With Partial Seizures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- Valexfarm · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is effictive and safe in patients with epilepsy with partial seizures
Detailed description
Phase III
Conditions
- Epilepsy
- Simple Partial Seizures
- Complex Partial Seizures
- Partial Seizures With Secondary Generalization
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remegal | Remegal 1500 mg for 12 weeks |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-10-01
- Completion
- 2013-12-01
- First posted
- 2012-12-13
- Last updated
- 2017-05-11
Locations
9 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT01749046. Inclusion in this directory is not an endorsement.